Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Paraganglioma × Observation × Endocrine × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Endocrine 1 CNS 1

Conditions

Pheochromocytoma 1 Paraganglioma 1 Osteoporosis 1 Obesity 1 Insulinoma 1 Hypertension 1 Hypercholesterolemia 1 Hyperaldosteronism 1 Growth Hormone-Secreting Pituitary Adenoma 1 Diabetes Mellitus 1 Cushing Syndrome 1 Cardiomyopathies 1 Carcinoma, Neuroendocrine 1 Adrenocortical Carcinoma 1 Adrenal incidentaloma 1 Adrenal Gland Neoplasms 1 Acromegaly 1

Interventions

3-Iodobenzylguanidine 7 lutetium Lu 177 dotatate 6 gallium Ga 68 dotatate 5 Specimen Handling 4 Magnetic Resonance Spectroscopy 4 Temozolomide 3 olaparib 2 belzutifan 2 anlotinib 2 Phenoxybenzamine 2 Nivolumab 2 Fluorodeoxyglucose F18 2 Everolimus 2 Biopsy 2 3-fluorobenzylguanidine 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 talazoparib 1 spartalizumab 1 pazopanib 1 lanreotide 1 guadecitabine 1 fludarabine phosphate 1 copper dotatate CU-64 1 cixutumumab 1 cabozantinib 1 atezolizumab 1 Vorinostat 1 Sunitinib 1 Salts 1 Radiosurgery 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05082311 2022-02-10

PheoCard

Sanjay Gandhi Postgraduate Institute of Medical Sciences

Cardiomyopathies, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡